Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
ONCASPAR Trockensub 3750 IE Durchstf
Drug
Oncaspar, poudre pour solution injectable
Oncaspar ist als Bestandteil einer antineoplastischen Kombinationstherapie bei akuter lymphatischer Leukämie (ALL) angezeigt
07.16.1. – cytostatics
HAM – Human medicine
PULVL – Powder for solution for injection
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
12/10/2018
12/31/9999
Dosage strength
Oncaspar 750 UI/ml, poudre pour solution injectable
Oncaspar est indiqué en association à d'autres agents antinéoplasiques pour le traitement de la leucémie lymphoblastique aiguë (LLA)
01
Z – approved
Package
7680669340018
In trade from / since 12/10/2018
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
3750 I.U. pegaspargasum
saccharum
natrii dihydrogenophosphas anhydricus
dinatrii phosphas
natrii chloridum
natrii hydroxidum
acidum hydrochloridum
12.47 mg natrium
natrii dihydrogenophosphas anhydricus
dinatrii phosphas
natrii chloridum
natrii hydroxidum
acidum hydrochloridum
12.47 mg natrium
Spezialitätenliste***
SL
-
-
1765.30
None
Yes
10%
No
Authorisation holder
7601001002371
Servier (Suisse) SA
La Voie-Creuse 16
1202 Genève (GE)
La Voie-Creuse 16
1202 Genève (GE)
Date of revision of the text
2/1/2026
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.